Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 5/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14131844 | 0.87 | PDE4B (0.54) | CTSLCTSKPDE4BITGB3ITGA2B | |
| SCHEMBL4791190 | 0.87 | PDE4B (0.54) | CTSLCTSKPDE4BITGB3ITGA2B | |
| SCHEMBL14145058 | 0.87 | PDE4B (0.54) | CTSLCTSKPDE4BITGB3ITGA2B | |
| SCHEMBL6600419 | 0.86 | CTSK (0.44) | CTSSCTSLCTSBCTSKPDE4B | |
| SCHEMBL6600917 | 0.83 | CTSS (0.45) | CTSSCTSLCTSBCTSKPDE4B | |
| SCHEMBL3218733 | 0.81 | CTSK (0.56) | CTSLCTSKPDE4BHSD11B1KMT2A | |
| SCHEMBL3218744 | 0.81 | CTSK (0.56) | CTSLCTSKPDE4BHSD11B1KMT2A | |
| SCHEMBL3218754 | 0.81 | CTSK (0.56) | CTSLCTSKPDE4BHSD11B1KMT2A | |
| SCHEMBL376621 | 0.81 | CTSK (0.56) | CTSLCTSKPDE4BHSD11B1KMT2A | |
| SCHEMBL2448494 | 0.81 | CTSK (0.56) | CTSLCTSKPDE4BHSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392657-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1392657-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040038965-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| WO-2003053331-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038965-A1 | Protease inhibitors | CTSK, CTSZ, CTSE | CTSS 6/4885CTSL 14/4885CTSB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.